Concepts (172)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 43 | 2024 | 1204 | 11.260 |
Why?
|
| Heart-Assist Devices | 38 | 2023 | 731 | 11.120 |
Why?
|
| Hemodynamics | 19 | 2023 | 710 | 3.770 |
Why?
|
| Aortic Valve Insufficiency | 9 | 2023 | 130 | 3.500 |
Why?
|
| Shock, Cardiogenic | 7 | 2023 | 95 | 2.550 |
Why?
|
| Heart Transplantation | 10 | 2024 | 705 | 2.080 |
Why?
|
| Heart Ventricles | 11 | 2023 | 760 | 1.980 |
Why?
|
| Echocardiography, Doppler | 7 | 2020 | 187 | 1.880 |
Why?
|
| Ventricular Function, Left | 8 | 2022 | 592 | 1.630 |
Why?
|
| Cardiac Catheterization | 6 | 2023 | 291 | 1.300 |
Why?
|
| Thrombosis | 2 | 2021 | 296 | 1.270 |
Why?
|
| Pulmonary Wedge Pressure | 6 | 2021 | 108 | 1.210 |
Why?
|
| Intra-Aortic Balloon Pumping | 6 | 2022 | 78 | 1.170 |
Why?
|
| Humans | 59 | 2024 | 86643 | 1.010 |
Why?
|
| Cardiac Output | 6 | 2023 | 156 | 0.960 |
Why?
|
| Heart Valve Prosthesis | 1 | 2023 | 93 | 0.890 |
Why?
|
| Aortic Valve | 5 | 2023 | 222 | 0.890 |
Why?
|
| Heart Valve Diseases | 1 | 2023 | 109 | 0.870 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2021 | 134 | 0.810 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2022 | 139 | 0.770 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2020 | 21 | 0.750 |
Why?
|
| Myocardial Infarction | 1 | 2023 | 376 | 0.740 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 183 | 0.730 |
Why?
|
| Coronary Artery Disease | 2 | 2016 | 350 | 0.710 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 115 | 0.710 |
Why?
|
| Prosthesis Implantation | 1 | 2020 | 125 | 0.680 |
Why?
|
| Palliative Care | 1 | 2020 | 257 | 0.660 |
Why?
|
| Catheter Ablation | 1 | 2020 | 233 | 0.640 |
Why?
|
| Middle Aged | 20 | 2024 | 25028 | 0.630 |
Why?
|
| Prognosis | 7 | 2022 | 3679 | 0.610 |
Why?
|
| Stroke Volume | 2 | 2021 | 456 | 0.600 |
Why?
|
| Male | 24 | 2024 | 40965 | 0.560 |
Why?
|
| Hepatitis C, Chronic | 1 | 2017 | 126 | 0.550 |
Why?
|
| Tissue Donors | 2 | 2023 | 463 | 0.530 |
Why?
|
| Retrospective Studies | 15 | 2023 | 8489 | 0.530 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2015 | 9 | 0.530 |
Why?
|
| Spinal Cord Stimulation | 1 | 2015 | 13 | 0.520 |
Why?
|
| Troponin T | 1 | 2015 | 37 | 0.510 |
Why?
|
| Acute Coronary Syndrome | 1 | 2015 | 45 | 0.500 |
Why?
|
| Coronary Artery Bypass | 1 | 2016 | 228 | 0.490 |
Why?
|
| Myocardial Contraction | 1 | 2015 | 244 | 0.480 |
Why?
|
| Female | 21 | 2024 | 44532 | 0.440 |
Why?
|
| Predictive Value of Tests | 5 | 2024 | 1673 | 0.430 |
Why?
|
| Aged | 11 | 2022 | 18415 | 0.420 |
Why?
|
| Blood Platelets | 1 | 2012 | 149 | 0.410 |
Why?
|
| Intensive Care Units | 1 | 2015 | 373 | 0.410 |
Why?
|
| Aspirin | 1 | 2012 | 156 | 0.390 |
Why?
|
| Hypertension, Pulmonary | 1 | 2015 | 346 | 0.390 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2012 | 134 | 0.390 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2016 | 516 | 0.390 |
Why?
|
| Prosthesis Design | 3 | 2023 | 278 | 0.390 |
Why?
|
| Sex Factors | 2 | 2023 | 1054 | 0.370 |
Why?
|
| Cardiac Resynchronization Therapy | 2 | 2021 | 68 | 0.350 |
Why?
|
| Liver Transplantation | 1 | 2017 | 1268 | 0.340 |
Why?
|
| Cannula | 2 | 2019 | 47 | 0.310 |
Why?
|
| Adult | 9 | 2024 | 25648 | 0.310 |
Why?
|
| Treatment Outcome | 10 | 2023 | 7993 | 0.300 |
Why?
|
| Prosthesis Failure | 2 | 2017 | 111 | 0.280 |
Why?
|
| Prospective Studies | 6 | 2021 | 4213 | 0.250 |
Why?
|
| Echocardiography | 3 | 2020 | 911 | 0.250 |
Why?
|
| Quality of Life | 3 | 2021 | 1585 | 0.240 |
Why?
|
| Cardiac Valve Annuloplasty | 1 | 2023 | 13 | 0.240 |
Why?
|
| Atrioventricular Block | 1 | 2023 | 23 | 0.230 |
Why?
|
| Heart | 2 | 2024 | 539 | 0.230 |
Why?
|
| Postoperative Complications | 4 | 2022 | 2207 | 0.230 |
Why?
|
| Cardiotonic Agents | 1 | 2023 | 87 | 0.220 |
Why?
|
| Aorta | 2 | 2021 | 280 | 0.220 |
Why?
|
| Reference Standards | 1 | 2023 | 159 | 0.220 |
Why?
|
| Thorax | 1 | 2023 | 75 | 0.220 |
Why?
|
| Atrial Pressure | 1 | 2021 | 6 | 0.210 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2023 | 111 | 0.210 |
Why?
|
| Waiting Lists | 1 | 2023 | 175 | 0.210 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2023 | 166 | 0.210 |
Why?
|
| Hydrodynamics | 1 | 2021 | 18 | 0.200 |
Why?
|
| Plasmapheresis | 1 | 2021 | 26 | 0.200 |
Why?
|
| Risk Assessment | 4 | 2024 | 2261 | 0.200 |
Why?
|
| Aortic Rupture | 1 | 2022 | 55 | 0.200 |
Why?
|
| Epoprostenol | 1 | 2021 | 46 | 0.200 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2021 | 25 | 0.200 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2022 | 93 | 0.190 |
Why?
|
| Torsion, Mechanical | 1 | 2020 | 6 | 0.190 |
Why?
|
| Heparin | 1 | 2021 | 175 | 0.190 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2020 | 44 | 0.190 |
Why?
|
| Counterpulsation | 1 | 2020 | 21 | 0.190 |
Why?
|
| Oxygen Consumption | 1 | 2021 | 239 | 0.190 |
Why?
|
| Exercise Test | 1 | 2021 | 164 | 0.180 |
Why?
|
| Exercise Tolerance | 1 | 2020 | 48 | 0.180 |
Why?
|
| Health Literacy | 1 | 2021 | 70 | 0.180 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2020 | 74 | 0.180 |
Why?
|
| Tissue and Organ Procurement | 1 | 2024 | 311 | 0.180 |
Why?
|
| Myocardium | 1 | 2022 | 529 | 0.170 |
Why?
|
| Pulmonary Artery | 1 | 2021 | 306 | 0.170 |
Why?
|
| Systole | 1 | 2019 | 129 | 0.170 |
Why?
|
| Anticoagulants | 1 | 2021 | 408 | 0.160 |
Why?
|
| Muscle Contraction | 1 | 2019 | 283 | 0.160 |
Why?
|
| Cardiomyopathies | 1 | 2020 | 240 | 0.150 |
Why?
|
| Reoperation | 1 | 2020 | 597 | 0.150 |
Why?
|
| Thermodilution | 1 | 2017 | 21 | 0.150 |
Why?
|
| Obesity, Morbid | 1 | 2020 | 225 | 0.150 |
Why?
|
| Computer Simulation | 1 | 2021 | 1078 | 0.140 |
Why?
|
| Equipment Safety | 1 | 2016 | 31 | 0.140 |
Why?
|
| Equipment Failure | 1 | 2016 | 119 | 0.140 |
Why?
|
| Atrial Septum | 1 | 2015 | 9 | 0.130 |
Why?
|
| Carotid Sinus | 1 | 2015 | 24 | 0.130 |
Why?
|
| Baroreflex | 1 | 2015 | 17 | 0.130 |
Why?
|
| Clinical Chemistry Tests | 1 | 2015 | 11 | 0.130 |
Why?
|
| Blood Flow Velocity | 1 | 2015 | 197 | 0.130 |
Why?
|
| Equipment and Supplies | 1 | 2015 | 30 | 0.130 |
Why?
|
| Equipment Design | 1 | 2016 | 406 | 0.130 |
Why?
|
| Cause of Death | 1 | 2016 | 277 | 0.130 |
Why?
|
| Biological Assay | 1 | 2015 | 78 | 0.130 |
Why?
|
| Reference Values | 1 | 2016 | 674 | 0.130 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 3640 | 0.130 |
Why?
|
| Electric Stimulation Therapy | 1 | 2015 | 51 | 0.130 |
Why?
|
| Observer Variation | 1 | 2016 | 602 | 0.120 |
Why?
|
| Stroke | 2 | 2020 | 965 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2022 | 2767 | 0.120 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 1801 | 0.120 |
Why?
|
| Endovascular Procedures | 1 | 2017 | 218 | 0.120 |
Why?
|
| Patient Selection | 2 | 2020 | 685 | 0.120 |
Why?
|
| Acute Disease | 1 | 2015 | 826 | 0.110 |
Why?
|
| Platelet Function Tests | 1 | 2012 | 11 | 0.110 |
Why?
|
| Platelet Aggregation | 1 | 2012 | 44 | 0.110 |
Why?
|
| Survival Rate | 1 | 2016 | 1863 | 0.100 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 977 | 0.100 |
Why?
|
| United States | 5 | 2024 | 6672 | 0.100 |
Why?
|
| Treatment Failure | 1 | 2012 | 285 | 0.100 |
Why?
|
| Risk Factors | 3 | 2024 | 5417 | 0.100 |
Why?
|
| Drug Resistance | 1 | 2012 | 256 | 0.100 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2705 | 0.090 |
Why?
|
| Biomarkers | 1 | 2015 | 1718 | 0.080 |
Why?
|
| alpha-Defensins | 1 | 2007 | 2 | 0.080 |
Why?
|
| Respiratory Mucosa | 1 | 2007 | 88 | 0.070 |
Why?
|
| Immunity | 1 | 2007 | 136 | 0.070 |
Why?
|
| Clinical Laboratory Services | 1 | 2024 | 4 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2007 | 425 | 0.060 |
Why?
|
| Bilirubin | 1 | 2024 | 125 | 0.060 |
Why?
|
| Health Care Rationing | 1 | 2024 | 83 | 0.060 |
Why?
|
| Tricuspid Valve | 1 | 2023 | 96 | 0.060 |
Why?
|
| Propensity Score | 1 | 2022 | 136 | 0.050 |
Why?
|
| Ventricular Pressure | 1 | 2021 | 34 | 0.050 |
Why?
|
| Time Factors | 2 | 2020 | 5210 | 0.050 |
Why?
|
| Axillary Artery | 1 | 2020 | 10 | 0.050 |
Why?
|
| Trauma Severity Indices | 1 | 2020 | 41 | 0.050 |
Why?
|
| Lung | 1 | 2007 | 1170 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 399 | 0.050 |
Why?
|
| Hemodynamic Monitoring | 1 | 2019 | 8 | 0.040 |
Why?
|
| Materials Testing | 1 | 2019 | 91 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 349 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2020 | 272 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 294 | 0.040 |
Why?
|
| Motivation | 1 | 2021 | 287 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 859 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 751 | 0.040 |
Why?
|
| Incidence | 1 | 2021 | 1577 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2020 | 329 | 0.040 |
Why?
|
| Obesity | 1 | 2023 | 963 | 0.040 |
Why?
|
| Disease Progression | 1 | 2020 | 1531 | 0.030 |
Why?
|
| Animals | 1 | 2015 | 26582 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2020 | 3612 | 0.030 |
Why?
|
| I-kappa B Proteins | 1 | 2007 | 53 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2007 | 86 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2007 | 101 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2007 | 249 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2007 | 89 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2007 | 420 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2007 | 444 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2007 | 381 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2007 | 444 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 1961 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2007 | 669 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2007 | 2818 | 0.010 |
Why?
|